High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance.
MCTS
PGE2
drug screen
mPGES-1
neuroblastoma
spheroids
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
revised:
09
06
2023
received:
21
02
2023
accepted:
28
07
2023
pubmed:
31
7
2023
medline:
31
7
2023
entrez:
31
7
2023
Statut:
aheadofprint
Résumé
High-throughput drug screening enables the discovery of new anticancer drugs. Although monolayer cell cultures are commonly used for screening, their limited complexity and translational efficiency require alternative models. Three-dimensional cell cultures, such as multicellular tumor spheroids (MCTS), mimic tumor architecture and offer promising opportunities for drug discovery. In this study, we developed a neuroblastoma MCTS model for high-content drug screening. We also aimed to decipher the mechanisms underlying synergistic drug combinations in this disease model. Several agents from different therapeutic categories and with different mechanisms of action were tested alone or in combination with selective inhibition of prostaglandin E
Identifiants
pubmed: 37519014
doi: 10.1002/1878-0261.13502
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Barncancerfonden
ID : PR2018-0055
Organisme : Barncancerfonden
ID : PR2020-0104
Organisme : Barncancerfonden
ID : TJ2017-0040
Organisme : Cancerfonden
ID : 19-0183
Organisme : Radiumhemmets Forskningsfonder
ID : 171073
Organisme : Vetenskapsrådet
ID : 2021-03420
Informations de copyright
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Sutherland RM, McCredie JA, Inch WR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst. 1971;46(1):113-120.
Steinmetz J, Senkowski W, Lengqvist J, Rubin J, Ossipova E, Herman S, et al. Descriptive proteome analysis to investigate context-dependent treatment responses to OXPHOS inhibition in colon carcinoma cells grown as monolayer and multicellular tumor spheroids. ACS Omega. 2020;5(28):17242-17254.
Hamilton G, Rath B. Applicability of tumor spheroids for in vitro chemosensitivity assays. Expert Opin Drug Metab Toxicol. 2019;15(1):15-23.
Gupta A, Gautam P, Wennerberg K, Aittokallio T. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Commun Biol. 2020;3(1):42.
Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res. 2001;7(9):2669-2674.
Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis R, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res. 2001;7(12):3971-3976.
Finetti F, Terzuoli E, Giachetti A, Santi R, Villari D, Hanaka H, et al. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocr Relat Cancer. 2015;22(4):665-678.
Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology. 2015;149(7):1884-1895.e4.
Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209-213.
Lin MC, Chen SY, He PL, Herschman H, Li HJ. PGE2/EP4 antagonism enhances tumor chemosensitivity by inducing extracellular vesicle-mediated clearance of cancer stem cells. Int J Cancer. 2018;143(6):1440-1455.
Larsson K, Kock A, Idborg H, Arsenian Henriksson M, Martinsson T, Johnsen JI, et al. COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci USA. 2015;112(26):8070-8075.
Kock A, Larsson K, Bergqvist F, Eissler N, Elfman LHM, Raouf J, et al. Inhibition of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts suppresses neuroblastoma tumor growth. EBioMedicine. 2018;32:84-92.
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174-186.
Kock A, Bergqvist F, Steinmetz J, Elfman LHM, Korotkova M, Johnsen JI, et al. Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting. FASEB J. 2020;34(8):11101-11114.
Larsson K, Steinmetz J, Bergqvist F, Arefin S, Spahiu L, Wannberg J, et al. Biological characterization of new mPGES-1 inhibitors in preclinical models of inflammation and vascular tone. Br J Pharmacol. 2019;176(24):4625-4638.
Sirenko O, Mitlo T, Hesley J, Luke S, Owens W, Cromwell EF. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Assay Drug Dev Technol. 2015;13(7):402-414.
Potdar S, Ianevski A, Mpindi JP, Bychkov D, Fiere C, Ianevski P, et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36(11):3602-3604.
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488-W493.
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739-W743.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
Langeback A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, et al. CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Sci Rep. 2019;9(1):19384.
Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11.
Rodrigues J, Heinrich MA, Teixeira LM, Prakash J. 3D in vitro model (r)evolution: unveiling tumor-stroma interactions. Trends Cancer. 2021;7(3):249-264.
Barbosa MA, Xavier CPR, Pereira RF, Petrikaitė V, Vasconcelos MH. 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancer. 2021;14(1):190.
Reidy E, Leonard NA, Treacy O, Ryan AE. A 3D view of colorectal cancer models in predicting therapeutic responses and resistance. Cancers (Basel). 2021;13(2):227.
Bell CR, Pelly VS, Moeini A, Chiang SC, Flanagan E, Bromley CP, et al. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat Commun. 2022;13(1):1-17.
Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522-526.
Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, et al. COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT axis. Stem Cells. 2016;34(9):2290-2305.
Elwakeel E, Brune B, Weigert A. PGE2 in fibrosis and cancer: insights into fibroblast activation. Prostaglandins Other Lipid Mediat. 2019;143:106339.
Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192(7):768-780.
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339-348.
Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, et al. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol. 2010;65(5):903-911.
Mason CW, Lee GT, Dong Y, Zhou H, He L, Weiner CP. Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells. Drug Metab Dispos. 2014;42(12):2077-2086.
Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002;277(41):38915-38920.
Liu B, Qu L, Tao H. Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol Int. 2009;34(1):21-25.
Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology. 2002;35(4):843-852.
Surowiak P, Pawełczyk K, Maciejczyk A, Pudełko M, Kołodziej J, Zabel M, et al. Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res. 2008;28(5B):2967-2974.
Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446(7137):749-757.
Helson L, Member B, Helson C. Importance of clinical exposure on verapamil enhancement of adriamycin-vincristine cytotoxicity in human neuroblastoma. Cancer Drug Deliv. 1984;1(4):303-305.
Simpson WG. The calcium channel blocker verapamil and cancer chemotherapy. Cell Calcium. 1985;6(6):449-467.
Feller N, Broxterman HJ, Währer DCR, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 1995;368(2):385-388.
Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem. 1993;268(29):21493-21496.
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. 2001;132(3):778-784.
Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010;12(10):1043-1049.
Roundhill EA, Burchill SA. Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br J Cancer. 2012;106(6):1224-1233.
Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, et al. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet. 2006;21(3):238-244.
Organization, B.I. New clinical development success rates 2011-2020 report. 2021.